Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

HOME I.V. MEDICARE FEE SCHEDULE REGS SHOULD BE READY IN SPRING 1989

Executive Summary

Proposed regs to set a per diem fee schedule for the ancillary services associated with home I.V. drug delivery under the Medicare outpatient drug program should be ready by the Spring of 1989, according to HCFA Office of Reimbursement Director Charles Booth. Booth told a Sept. 15 conference on Medicare coverage and reimbursement that the Health Care Financing Administration will have to try to have the proposed regs out early next year if the final rules are to be ready by the Fall of next year. That deadline is necessary so that HCFA can have the benefit ready to start by Jan. 1990, as specified by the Catastrophic Care Act. "There are a number of considerations that we will have to make in order to set up this fee schedule," Booth observed. One of the key questions,he said, will be the level of training a person needs to administer the therapy. Another issue will be the length of therapy. Transportation costs, supplies, inventory and overhead will also need to be addressed. HCFA is also prepared to look into safety needs, such as special preparation, handling and disposal of cytotoxins. Booth said HCFA expects there "will be significant comments regardless of what we come up with." He said that the "rulemaking process will be very important for this particular benefit."

Latest Headlines
See All
UsernamePublicRestriction

Register

PS014295

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel